Waleed Z Butt1,2, Jennifer K Yee3,4. 1. Division of Endocrinology, Department of Internal Medicine, Harbor-UCLA Medical Center, 1000 W. Carson Street, Harbor Box 446, Torrance, CA, 90509, USA. 2. The Lundquist Institute of Biomedical Innovation at Harbor, UCLA Medical Center, 1124 W. Carson Street, Martin Building, Torrance, CA, 90502, USA. 3. The Lundquist Institute of Biomedical Innovation at Harbor, UCLA Medical Center, 1124 W. Carson Street, Martin Building, Torrance, CA, 90502, USA. jyee@lundquist.org. 4. Division of Endocrinology, Department of Pediatrics, Harbor-UCLA Medical Center, 1000 W. Carson Street, Harbor Box 446, Torrance, CA, 90509, USA. jyee@lundquist.org.
Abstract
PURPOSE OF REVIEW: Lifestyle modification is additive to lipid-lowering medications in the treatment of heterozygous familial hypercholesterolemia (HeFH), which does not respond sufficiently to statin therapy. While both are also important in homozygous familial hypercholesterolemia (HoFH), additional measures such as apheresis may be needed. The purpose of this review is to identify non-statin medications to lower cholesterol that are available for children and adolescents as adjunctive therapy. RECENT FINDINGS: Ezetimibe is commonly used as second-line pharmacotherapy for treatment of HeFH and HoFH. Colesevelam, a bile acid sequestrant, may be considered for adjunct therapy. Since 2015, the PCSK9 inhibitor evolocumab has been available for adolescents, and its FDA approval has now expanded to age 10 years. The ANGPTL3 inhibitor evinacumab has been approved for children age 12 years and older. A clinical trial for lomitapide is in progress. Approvals for PCSK9 and ANGPTL3 inhibitors have expanded opportunities for children and adolescents with HeFH and HoFH to achieve lower LDL-C levels.
PURPOSE OF REVIEW: Lifestyle modification is additive to lipid-lowering medications in the treatment of heterozygous familial hypercholesterolemia (HeFH), which does not respond sufficiently to statin therapy. While both are also important in homozygous familial hypercholesterolemia (HoFH), additional measures such as apheresis may be needed. The purpose of this review is to identify non-statin medications to lower cholesterol that are available for children and adolescents as adjunctive therapy. RECENT FINDINGS: Ezetimibe is commonly used as second-line pharmacotherapy for treatment of HeFH and HoFH. Colesevelam, a bile acid sequestrant, may be considered for adjunct therapy. Since 2015, the PCSK9 inhibitor evolocumab has been available for adolescents, and its FDA approval has now expanded to age 10 years. The ANGPTL3 inhibitor evinacumab has been approved for children age 12 years and older. A clinical trial for lomitapide is in progress. Approvals for PCSK9 and ANGPTL3 inhibitors have expanded opportunities for children and adolescents with HeFH and HoFH to achieve lower LDL-C levels.
Authors: Scott M Grundy; Neil J Stone; Alison L Bailey; Craig Beam; Kim K Birtcher; Roger S Blumenthal; Lynne T Braun; Sarah de Ferranti; Joseph Faiella-Tommasino; Daniel E Forman; Ronald Goldberg; Paul A Heidenreich; Mark A Hlatky; Daniel W Jones; Donald Lloyd-Jones; Nuria Lopez-Pajares; Chiadi E Ndumele; Carl E Orringer; Carmen A Peralta; Joseph J Saseen; Sidney C Smith; Laurence Sperling; Salim S Virani; Joseph Yeboah Journal: Circulation Date: 2018-11-10 Impact factor: 29.690
Authors: Amanda M Perak; Hongyan Ning; Brian K Kit; Sarah D de Ferranti; Linda V Van Horn; John T Wilkins; Donald M Lloyd-Jones Journal: JAMA Date: 2019-05-21 Impact factor: 56.272
Authors: Sarah D de Ferranti; Angie Mae Rodday; Michael M Mendelson; John B Wong; Laurel K Leslie; R Christopher Sheldrick Journal: Circulation Date: 2016-03-15 Impact factor: 29.690
Authors: Gregory A Roth; George A Mensah; Catherine O Johnson; Giovanni Addolorato; Enrico Ammirati; Larry M Baddour; Noël C Barengo; Andrea Z Beaton; Emelia J Benjamin; Catherine P Benziger; Aimé Bonny; Michael Brauer; Marianne Brodmann; Thomas J Cahill; Jonathan Carapetis; Alberico L Catapano; Sumeet S Chugh; Leslie T Cooper; Josef Coresh; Michael Criqui; Nicole DeCleene; Kim A Eagle; Sophia Emmons-Bell; Valery L Feigin; Joaquim Fernández-Solà; Gerry Fowkes; Emmanuela Gakidou; Scott M Grundy; Feng J He; George Howard; Frank Hu; Lesley Inker; Ganesan Karthikeyan; Nicholas Kassebaum; Walter Koroshetz; Carl Lavie; Donald Lloyd-Jones; Hong S Lu; Antonio Mirijello; Awoke Misganaw Temesgen; Ali Mokdad; Andrew E Moran; Paul Muntner; Jagat Narula; Bruce Neal; Mpiko Ntsekhe; Glaucia Moraes de Oliveira; Catherine Otto; Mayowa Owolabi; Michael Pratt; Sanjay Rajagopalan; Marissa Reitsma; Antonio Luiz P Ribeiro; Nancy Rigotti; Anthony Rodgers; Craig Sable; Saate Shakil; Karen Sliwa-Hahnle; Benjamin Stark; Johan Sundström; Patrick Timpel; Imad M Tleyjeh; Marco Valgimigli; Theo Vos; Paul K Whelton; Magdi Yacoub; Liesl Zuhlke; Christopher Murray; Valentin Fuster Journal: J Am Coll Cardiol Date: 2020-12-22 Impact factor: 24.094